¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Familial amyotrophic lateral sclerosis"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • lateral decubitus position
    ¿·´©¿îÀÚ¼¼, ¸ð·Î´©¿îÀÚ¼¼
  • lateral epicondylitis
    °¡ÂÊÀ§°üÀýÀ¶±â¿°, ¿ÜÃø»ó°ú¿°
  • lateral gastrocnemius bursa
    °¡ÂÊÀåµýÁö±ÙÁÖ¸Ó´Ï, ¿ÜÃøºñº¹±Ù³¶
  • lateral geniculate body
    °¡Âʹ«¸­Ã¼, ¿ÜÃø½½»óü
  • lateral hermaphroditism
    °¡Âʳ²³àÇѸöÁõ
  • lateral horn
    °¡ÂÊ»Ô
  • lateral lacuna
    °¡Âʰø°£
  • lateral lemniscus
    °¡Âʼ¶À¯¶ì, ¿ÜÃø¼¶À¯´ë
  • lateral ligament
    °¡ÂÊÀδë, ¿ÜÃøÀδë
  • lateral malleolar network
    °¡Âʺ¹»çµ¿¸Æ±×¹°, ¿ÜÃøº¹»çµ¿¸Æ¸Á
  • lateral mass
    °¡Âʵ¢ÀÌ
  • lateral maxillary buttress
    °¡ÂÊÀ§ÅλÀ¹öÆÀº®
  • lateral meniscus
    °¡ÂʹݴÞ, ¿ÜÃø¹Ý¿ù
  • lateral nasal cartilage
    °¡ÂÊÄÚ¿¬°ñ, ¿ÜÃøºñ¿¬°ñ
  • lateral nasal prominence
    °¡ÂÊÄÚÀ¶±â, ¿ÜÃøºñÀ¶±â
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • lateral decubitus
    ¿·´©¿ò, Ãø¿ÍÀ§, ¿·´©¿îÀÚ¼¼
  • lateral cerebral fossa
    ´ë³ú°¡ÂÊ¿À¸ñ
  • lateral corporal fold
    ¸öÅë°¡ÂÊÁÖ¸§
  • retrograde lateral plantar artery flap
    ¿ªÇà°¡Âʹ߹ٴڵ¿¸ÆÇÇÆÇ, ¿ªÇà¿ÜÃøÁ·Àúµ¿¸ÆÇÇÆÇ
  • lateral hermaphroditism
    °¡Âʳ²³àÇѸöÁõ
  • lateral horn
    °¡ÂÊ»Ô
  • lateral
    °¡ÂÊ-, ¿ÜÃø-
  • lateral lacuna
    °¡Âʰø°£
  • lateral lemniscus
    °¡Âʼ¶À¯¶ì
  • lateral ligament
    °¡ÂÊÀδë
  • lateral mass
    °¡Âʵ¢ÀÌ
  • lateral meniscus
    °¡ÂÊÃʽ´Þ, °¡ÂʹݴÞ
  • lateral occlusion
    °¡Âʹ°¸², Ãø¹æ±³ÇÕ
  • lateral projection
    Ãø¸éÅõ¿µ¹ý
  • lateral sinus
    °¡Âʱ¼
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • primary posterolateral sclerosis
    ¿ø¹ß(¼º) ÈÄ¿ÜÃø»è°æÈ­(Áõ).
  • primary posterolateral sclerosis
    ¿ø¹ß(¼º) ÈÄ¿ÜÃø»è°æÈ­(Áõ)(ê«Û¡(àõ) ý­èâö°ßãÌãûù(ñø))
  • progressive systemic sclerosis
    ÁøÇ༺ Àü½Å °æÈ­Áõ
  • progressive systemic sclerosis
    ÁøÇ༺ Àü½Å¼º °æÈ­Áõ(Ìãûùñø)
  • progressive systemic sclerosis
    ÁøÇà(¼º) Àü½Å°æÈ­Áõ
  • progressive systemic sclerosis
    ÁøÇ༺ Àü½Å°æÈ­Áõ
  • progressive systemic sclerosis
    ÁøÇ༺ Àü½Å¼º °æÈ­Áõ(òäú¼àõ îñãóàõ Ìãûùñø)
  • progressive systemic sclerosis
    ÁøÇ༺ Àü½Å¼º °æÈ­Áõ(òäú¼àõîñãóàõÌãûùñø).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • progressive systemic sclerosis
    ÁøÇ༺ Àü½Å¼º °æÈ­Áõ(òäú¼àõ îñãóàõ Ìãûùñø)
  • progressive systemic sclerosis
    ÁøÇà(¼º) Àü½Å°æÈ­Áõ
  • progressive systemic sclerosis
    ÁøÇ༺ Àü½Å¼º °æÈ­Áõ(òäú¼àõîñãóàõÌãûùñø).
  • progressive systemic sclerosis
    ÁøÇ༺ Àü½Å °æÈ­Áõ
  • progressive systemic sclerosis
    ÁøÇ༺ Àü½Å¼º °æÈ­Áõ(Ìãûùñø)
  • sclerosis
  • sclerosis mammae
    À¯¼±°æÈ­Áõ(êáàÍ Ìãûùñø).
  • sclerosis mammae
    À¯¼±°æÈ­Áõ(êáàÍÌãûùñø)
  • sclerosis of cornea
    °¢¸·°æÈ­(Áõ)
  • syphilitic aortic sclerosis
    ¸Åµ¶¼º ´ëµ¿¸Æ°æÈ­(Áõ)(¡­ÓÞÔÑØæÌãûùñø).
  • systemic sclerosis
    Àü½Å¼º °æÈ­(Áõ)
  • systemic sclerosis [=scleroderma]
    Àü½Å¼º°æÈ­Áõ[= °æÇÇÁõ]
  • tuberose sclerosis
    °áÀý¼º °æÈ­Áõ(Ì¿ï½àõÌãûùñø).
  • tuberose sclerosis
    °áÀý¼º °æÈ­Áõ(Ì¿ï½àõÌãûùñø)
  • tuberous sclerosis
    °áÀý¼º°æÈ­Áõ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • Posterior lateral nasal arteries
    °¡ÂʵÚÄÚµ¿¸Æ
    [¿¾ ¿ë¾î] ¿ÜÃøÈĺñµ¿¸Æ
  • Lateral occipitotemporal gyrus
    °¡ÂʵÚÅë¼ö°üÀÚÀ̶û
    [¿¾ ¿ë¾î] ¿ÜÃøÈĵÎÃøµÎȸ
  • Lateral occipital artery
    °¡ÂʵÚÅë¼ö¿±µ¿¸Æ
    [¿¾ ¿ë¾î] ¿ÜÃøÈĵÎÁö
  • Lateral dorsal nerve of great toe
    °¡ÂʵîÂʾöÁö¹ß°¡¶ô½Å°æ
    [¿¾ ¿ë¾î] ¹«Áö¿ÜÃø¹èÃøÁö½Å°æ
  • Lateral lymph nodes
    °¡Âʸ²ÇÁÀý
    [¿¾ ¿ë¾î] ¿ÜÃøÀÓÆÄÀý
  • Lateral mallear ligament
    °¡ÂʸÁÄ¡Àδë
    [¿¾ ¿ë¾î] ¿ÜÃøÃß°ñÀδë
  • Lateral surface
    °¡Âʸé
    [¿¾ ¿ë¾î] ¿ÜÃø¸é
  • Lateral surface
    °¡Âʸé
    [¿¾ ¿ë¾î] ¿ÜÃø¿¬
  • Lateral border
    °¡Âʸ𼭸®
    [¿¾ ¿ë¾î] ¿ÜÃø¿¬
  • Lateral margin
    °¡Âʸ𼭸®
    [¿¾ ¿ë¾î] ¿ÜÃø¿¬
  • Lateral marginal vein
    °¡Âʸ𼭸®Á¤¸Æ
    [¿¾ ¿ë¾î] ¿ÜÃø¿¬Á¤¸Æ
  • Lateral cervical lymph nodes
    °¡Âʸñ¸²ÇÁÀý
    [¿¾ ¿ë¾î] ¿ÜÃø°æÀÓÆÄÀý
  • Lateral talocalcaneal ligament
    °¡Âʸñ¸»¹ß²ÞÄ¡Àδë
    [¿¾ ¿ë¾î] ¿ÜÃø°ÅÁ¾Àδë
  • Lateral patellar retinaculum
    °¡Âʹ«¸­ÁöÁö¶ì
    [¿¾ ¿ë¾î] ¿ÜÃø½½°³Áö´ë
  • Lateral geniculate body
    °¡Âʹ«¸­Ã¼
    [¿¾ ¿ë¾î] ¿ÜÃø½½»óü
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
ASO   1) Arterio-Sclerosis Obliterans
  2) Anti-Streptolysin O; - 166
FSGS Focal Segmental Glomerulo-Sclerosis
MS   1) Mitral Stenosis
  2) Multiple Sclerosis; ´Ù¹ß¼º °æÈ­Áõ
  3) Macro...
NS   1) Nephrotic Syndrome
    1. Proteinuria
   &nb...
SSc Systemic Sclerosis
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
CDMS clinically definite multiple sclerosis
DS disseminated sclerosis
FSGS focal segmental glomerular sclerosis
RR MS relapsing remitting multiple sclerosis
scleroderma sclerosis
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • lateral basal segment
    °¡ÂÊ ¹Ù´Ú ±¸¿ª
  • lateral bicipital groove
    °¡ÂÊ µÎ °¥·¡ ±Ù °í¶û
  • lateral border
    °¡ÂÊ ¸ð¼­¸®
  • lateral border movement
    Ãø¹æ ÇÑ°è ¿îµ¿
  • lateral border of tibia
    °ñ°£ ¿¬
  • lateral brainstem
    ¿ÜÃø ³ú°£
  • lateral branch of posterior intercostal artery
    ÈÄ´Á°£ µ¿¸ÆÀÇ ¿ÜÃø Áö
  • lateral bursa of gastrocnemius muscle
    ºñº¹±Ù ¿ÜÃø °Ç Çϳ¶
  • lateral canal
    Ãø¹æ °ü
    ÁÖÄ¡±Ù°ü¿¡¼­ºÎÅÍ Á÷°¢¿¡ °¡±õ°Ô ³ª´©¾îÁ®¼­ Ä¡±ÙÀÇ ¿Ü¸é¿¡ °³±¸ÇÏ´Â °¡´Â °ü. ÃøÁö¶ó°íµµ Çϸç Hertwig »óÇÇ »Ñ¸®ÁýÀÇ ¿¬°áÀÌ ²÷¾îÁø ºÎÀ§¿¡¼­ »ó¾ÆÁú ¸ð¼¼Æ÷°¡ À¯µµµÇÁö ¾Ê¾Æ »ý±â´Â °ÍÀ¸·Î Ç÷°ü°ú ½Å°æÀÌ ºÐÆ÷ÇØ¼­ ÀÓ»óÀûÀ¸·Î Áß¿äÇÑ ºÎÀ§.
  • lateral canthus
    ¿ÜÃø ´« ±¸¼®, ¿Ü¾È°¢
  • lateral caval lymph node
    °¡ÂÊ ¾Æ·¡ ´ëÁ¤¸Æ ¸²ÇÁÀý
  • lateral cerebral fissure
    ¿ÜÃø ´ë³ú ¿­, ¿ÜÃø±¸
  • lateral cervical fistula
    Ãø°æ·ç
  • lateral chain
    Ãø¼â
  • lateral circumflex femoral artery
    ¿ÜÃø ´ëÅð ȸ¼± µ¿¸Æ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
progressive familial scleroderma A syndrome characterised by calcinosis cutis, Raynaud's phenomenon, sclerodactyly, and telangiectasia; usually due to scleroderma; autosomal dominant form of progressive systemic sclerosis.
(05 Mar 2000)
hypercholesterolaemia, familial A familial disorder characterised by increased plasma concentration of cholesterol carried in low density lipoproteins (ldl) and by a deficiency in a cell surface receptor which regulates ldl degradation and cholesterol synthesis. It is frequently associated with arcus senilis and premature atherosclerosis.
(12 Dec 1998)
hyperlipidemia, familial combined A disorder genetically distinct from the other inherited hyperlipidemias characterised by the type II or type IV lipoprotein pattern (the pattern may change from time to time and the lipid level may be normal at one time and abnormal at another time).
(12 Dec 1998)
hypophosphatemia, familial Familial disorder characterised by hypophosphatemia associated with decreased renal tubular reabsorption of inorganic phosphorus. It is sometimes associated with osteomalacia or rickets which do not respond to the usual doses of vitamin d.
(12 Dec 1998)
Danubian endemic familial nephropathy A tubulointerstitial disease of unknown aetiology occurring in a limited geographic area including adjacent regions of romania, bulgaria, and yugoslavia.
(12 Dec 1998)
dysautonomia, familial An autosomal recessive inherited disorder seen predominantly in jewish infants and children. The peripheral autonomic and sensory neurons are affected. The characteristic distinguishing this disorder from other hereditary sensory and autonomic neuropathies is the predominance of autonomic symptoms such as excessive perspiration, defective lacrimation, and hypertension. Insensitivity to pain and areflexia are also present.
(12 Dec 1998)
type I familial hyperlipoproteinaemia Hyperlipoproteinaemia characterised by the presence of large amounts of chylomicrons and triglycerides in the plasma when the patient has a normal diet, and their disappearance on a fat-free diet; low alpha-and beta-lipoproteins on a normal diet, with increase on fat-free diet; decreased plasma postheparin lipolytic activity; and low tissue lipoprotein lipase activity. It is accompanied by bouts of abdominal pain, hepatosplenomegaly, pancreatitis, and eruptive xanthomas; autosomal recessive inheritance.
See: familial lipoprotein lipase inhibitor.
Synonym: Burger-Grutz syndrome, familial fat-induced hyperlipaemia, familial hyperchylomicronaemia, familial hypertriglyceridemia, idiopathic hyperlipaemia.
(05 Mar 2000)
type II familial hyperlipoproteinaemia Hyperlipoproteinaemia characterised by increased plasma levels of beta-lipoproteins, cholesterol, and phospholipids, but normal triglycerides; heterozygotes have mild lipid changes and are susceptible to atherosclerosis in middle age, but homozygotes have severe changes often with generalised xanthomatosis and xanthelasma, and frank clinical atherosclerosis as young adults. The primary defect is a deficiency of apoprotein of VLDL, and the disorder is divided into two classes: 1) type IIA, which has elevated LDL due to a deficiency of the receptor or a modified apolipoprotein B-100; 2) type IIB, which has elevated LDL and triglycerides; autosomal dominant inheritance.
Synonym: familial hyperbetalipoproteinaemia, familial hypercholesteraemic xanthomatosis, familial hypercholesterolaemia.
(05 Mar 2000)
type III familial hyperlipoproteinaemia Hyperlipoproteinaemia characterised by increased plasma levels of LDL, beta-lipoproteins, pre-beta-lipoproteins, cholesterol, phospholipids, and triglycerides; hypertriglyceridemia induced by a high carbohydrate diet, and glucose tolerance is abnormal; frequent eruptive xanthomas and atheromatosis, particularly coronary artery disease; biochemical defect lies in apolipoproteins; there are many varieties.
Synonym: carbohydrate-induced hyperlipaemia, dysbetalipoproteinaemia, familial hyperbetalipoproteinaemia and hyperprebetalipoproteinaemia, familial hypercholesterolaemia with hyperlipaemia.
(05 Mar 2000)
type IV familial hyperlipoproteinaemia Plasma levels of VLDL, pre-beta-lipoproteins and triglycerides are increased on a normal diet, but beta-lipoproteins, cholesterol, and phospholipids are normal; hypertriglyceridemia is induced by a high carbohydrate diet; may be accompanied by abnormal glucose tolerance and susceptibility to ischemic heart disease; probably autosomal recessive inheritance.
Synonym: carbohydrate-induced hyperlipaemia, familial hyperprebetalipoproteinaemia, familial hypertriglyceridemia.
(05 Mar 2000)
type V familial hyperlipoproteinaemia Hyperlipoproteinaemia characterised by increased plasma levels of chylomicrons, VLDL, pre-beta-lipoproteins, and triglycerides, and slight rise of cholesterol on a normal diet, with beta-lipoproteins normal; may be accompanied by bouts of abdominal pain, hepatosplenomegaly, susceptibility to atherosclerosis, and abnormal glucose tolerance; probably autosomal recessive inheritance.
Synonym: combined fat-and carbohydrate-induced hyperlipaemia, familial hyperchylomicronaemia with hyperprebetalipoproteinaemia, mixed hyperlipaemia.
(05 Mar 2000)
familial Occurring in families. An inherited disorder or trait.
(27 Sep 1997)
familial adenomatous polyposis <gastroenterology> Genetic disease with numerous precancerous polyps in the colon and rectum. Also called familial polyposis.
(12 Dec 1998)
familial aggregation <genetics> The occurrence of a trait in more members of a family than can be readily accounted for by chance; presumptive but not cogent evidence of the operation of genetic factors.
(05 Mar 2000)
familial amyloid neuropathy <neurology> A disorder in which various peripheral nerves are infiltrated with amyloid and their functions disturbed, an abnormal prealbumin is also formed and is present in the blood; characteristically, it begins during mid-life and is found largely in persons of Portuguese descent. Other rare clinical types occur.
Inheritance: autosomal dominant.
Synonym: familial amyloidosis, hereditary amyloidosis.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á